1. ¿Qué tratamientos farmacológicos se recomiendan condicionalmente para pacientes adultos con riesgo muy alto de fractura por GIOP?
2. Which osteoporosis medications are strongly recommended for adults ≥40 years with high or very high risk of fracture due to glucocorticoid-induced osteoporosis (GIOP)?
3. ¿Cuál es la dosis mínima de glucocorticoides a partir de la cual se recomienda evaluar el riesgo de osteoporosis inducida por glucocorticoides (GIOP)?
4. Which bone mineral density (BMD) T-score thresholds correspond to low, moderate, high, and very high fracture risk in glucocorticoid-treated adults?
5. For adults ≥40 years at moderate fracture risk receiving glucocorticoid therapy, what osteoporosis treatments are conditionally recommended?
6. What are the major considerations when deciding to use anabolic agents as initial therapy in glucocorticoid-induced osteoporosis?
7. ¿Cuáles son las categorías de riesgo de fractura establecidas en la guía para pacientes con osteoporosis inducida por glucocorticoides?
8. What is the role of parathyroid hormone (PTH) or PTH-related protein (PTHrP) agonists in the management of GIOP?
9. ¿Qué precauciones se deben tener con la discontinuación del denosumab (DEN) en el tratamiento de GIOP?
10. What is the recommended management of osteoporosis therapy in adults who discontinue glucocorticoids and have no new fragility fractures with a current BMD T-score ≥ -2.5?
11. When might switching from oral bisphosphonates to intravenous bisphosphonates, denosumab, romosozumab, or PTH/PTHrP be recommended in glucocorticoid-induced osteoporosis?
12. How should treatment strategies differ for patients receiving high-dose glucocorticoids (≥30 mg/day for >30 days or cumulative ≥5 g/year)?
13. What fracture risk assessment tools or adjustments are suggested for patients on glucocorticoids?
14. What is the risk associated with discontinuation of denosumab after two or more doses, and what is the recommended follow-up treatment?
15. What fracture types are included in the definition of major osteoporotic fractures (MOF) in GIOP?
16. How is the FRAX tool adjusted for glucocorticoid use when assessing fracture risk in adults ≥40 years old?
17. Why is switching from denosumab to PTH/PTHrP not recommended in glucocorticoid-induced osteoporosis?
18. Why should bisphosphonates be avoided in patients with advanced CKD undergoing treatment for glucocorticoid-induced osteoporosis?
19. ¿Qué efectos adversos importantes se asocian con el uso de bisfosfonatos intravenosos, denosumab y romosozumab en el tratamiento de la osteoporosis inducida por glucocorticoides?
20. What lifestyle modifications are recommended alongside pharmacologic treatment for prevention of glucocorticoid-induced osteoporosis?